An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Ardent Health, Inc.
VERDICT
The label
Markup
read at $10.15
Ardent Health, Inc. holds its Markup at $10.15.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 8 days
Price
$10.15
Valuation
10.80 trailing · 8.15 forward price to earnings
Values screen
PASS· score 70.0
Beta
N/A
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$10.15
10.80 P/E · 8.15 fwd
Our fair value
$14.00
38% discount
Analyst target (avg)
$12.00
+18% to current
Target low $9.00Analyst target rangeTarget high $14.00
▲ current $10.15 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$10.15
you are here
Conservative
$14.00
+38%
Analyst avg
$12.00
+18%
Our fair value
$14.00
+38%
Analyst high
$14.00
+38%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
7.00%
Profit margin
2.09%
Debt to equity
132.31
Analyst consensus
Buy · 11 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
It depends which standard you follow. There are two widely recognised ways to check whether a company is suitable for a Muslim investor, and on this company they disagree. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✓ PASSES
Why the two disagree. They fall out over one thing only: the company’s debt. Our stricter standard measures that debt against what the company owns, and it works out too high to pass. The common standard measures the same debt against what the company is worth on the stock market, where it works out low enough to pass. Every other check, the two agree on. So in practice, most halal apps would treat this as fine to hold, while our stricter view would not — and which line you follow is between you and your scholar.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows. Against market value it is 157.4%, under the 30% line the market-value standard uses — so that standard clears it.Divergent
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Hospitals Treating Real Patients Trade at a Discount
Picture a local clinic where a family gets care after an accident or a routine check. The cash still has to flow through operators that run dozens of these sites across states. Ardent Health owns and manages that network yet carries an opportunity rating of none despite a forward multiple of 8.2 times and revenue growth near 7 percent.
The balance sheet shows a 2 percent profit margin alongside 14 percent return on equity and an ethical screen that clears cleanly. Analyst consensus sits at buy with a median target of 12 dollars. Those figures look steady on paper but the unknown moat and slim margins leave little room for error when reimbursement rates shift.
Healthcare operators face constant pressure from regulation and payer mix that can erode even modest profits quickly. Thin returns also mean any slowdown in patient volumes hits earnings hard and leaves valuation looking less attractive than it first appears. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
ARDT trades on the NYSE. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12. Entered 2026-07-21 · Accumulation
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12.
2026-07-18Distribution$9.35+0.0%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12.
2026-07-17Distribution$9.35+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (11 analysts) rates it none, with a mean price target of $12.
2026-07-03Distribution$9.35+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$9.35Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$9.95
-5.8%
·
$942
-5.8%
2 months
$9.40
-0.3%
·
$997
-0.3%
3 months
$9.24
+1.4%
·
$1,014
+1.4%
6 months
$8.73
+7.3%
·
$1,073
+7.3%
1 year
$13.42
-30.2%
·
$698
-30.2%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever ARDT does next, these words stay.
Ardent Health, Inc. · ARDT · Markup · $10.15
Recorded 2026-07-19 · before the outcome · scored mechanically
